

Indivior PLC – Appointment of Chief Financial Officer

Slough, UK, and Richmond, VA, November 20, 2020 – The Board of Directors of Indivior PLC are pleased to announce the appointment of Ryan Preblich as Chief Financial Officer and Executive Director with immediate effect.

Ryan has been serving as Interim Chief Financial Officer since June 2020 and has been in financial leadership roles since joining Indivior in 2012. Prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Financial Planning and Analysis Commercial Operations. This role included overseeing all key financial management, analysis and reporting elements of the Group’s global business. Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial areas of the US business, the Group’s largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations.

Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Philip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support. Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.

Comment by Mark Crossley, Chief Executive Officer

Ryan has proven to be a highly capable leader of our finance organization and has performed strongly in his role as Interim Chief Financial Officer. The Board and I are delighted to confirm his appointment as Chief Financial Officer and Executive Director.

The Company confirms there is no further information to be disclosed pursuant to LR 9.6.13 in connection with Ryan Preblich’s appointment.

About Indivior

Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Investor Contact:

Jason Thompson, Indivior
Vice President, Investor Relations
+1 804-402-7123
Jason.Thompson@indivior.com

Media Contacts:

UK
Tulchan Communications
+44 207-353-4200

US
IndiviorMediaContacts@indivior.com
+1 804-594-0836

-ends-